Press Releases

Press Releases

New functionality provides a straightforward method for radiologists to indicate the first imaging test, or sign or symptom that triggered subsequent workup and diagnosis of breast cancer

Apollo introduces a groundbreaking new eBook, Delivering relevant medical images across the continuum of care, which introduces a paradigm shift in enterprise imaging, explaining how a multi-disciplinary, patient-centric approach supports thinking beyond the radiology workflow to reflect both the workflows of other specialties and medical encounters.

Patients and Physicians in Northeast Florida have been demanding a new type of patient-centric healthcare service. By partnering with Idonia, Precision Imaging Centers is answering that demand.

 

TIMS Medical releases TIMS MVP 5.0, a major new upgrade to its flagship product for recording, editing and archiving MBS, FEES and endoscopy studies in high-resolution video with synced audio.

Orthoscan announced the End of Life (EOL) plan for its Orthoscan FD, FD-OR, Mobile DI (MDI), and FD Pulse Mini C-Arms. 

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of patient enrollment in the company’s pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance®.

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Award-winning company expands its U.S. warehouse with high-quality Mini C-Arm refurbishment center.

Nov 29, 2022 | Submitted by: Ascelia Pharma

23 November 2022: Ascelia Pharma AB (publ) – a biopharmaceutical company focused on improving the life of people living with rare cancer conditions –  is presenting results from its Orviglance* Food Effect study at the RSNA conference 2022 (Radiological Society of North America – 27 November – 1 December Chicago, Illinois). The study evaluates the effect of food intake on the absorption and signal intensity of Orviglance, a manganese-based MRI contrast agent, and successfully concludes that image enhancement is not impacted by a light meal.

Triad Isotopes, Inc. (Triad) has announced the addition of two nationally-recognized executives to the company’s leadership team.  Kerry E. Gillespie, CPA, CGMA has joined the company as Chief Financial Officer (CFO) and Chief Operations Officer (COO).  Douglas Ash has joined the company as Chief Information Officer (CIO).  Both report to Dom Meffe, President & Chief Executive Officer (CEO).

Truven Health Analytics and the Georgia Department of Community Health announced today the launch of a statewide health information exchange (HIE) network, known as the Georgia Health Information Network (GaHIN).

AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the enrollment of the first patient at University of Miami Hospital in a randomized multi-center study investigating whether the BioFlo PICC will be associated with a reduced incidence of catheter-related venous thrombosis, including both symptomatic and asymptomatic, compared to another commercially available PICC, the Bard PowerPICC SOLO2.

Phytel, the leader in automated, provider-led population health improvement, has been selected to demonstrate its advanced care management technology at the upcoming Health 2.0 conference, which will take place October 7-11 at the Santa Clara Convention Center in Santa Clara, Calif.

Greenway Medical Technologies announces an alliance with Harland Technology Services to support small to medium-sized ambulatory healthcare practices in implementing advanced health information technology (HIT) solutions.

At the recent GEMMS Annual User Group Conference, GEMMS announced the immediate availability of several new low cost GEMMS interface packages. GEMMS, a leader in specialty based EHR, has leveraged its GEMMS LINK technology to interoperability solutions that are low cost and which can be deployed rapidly. "For years our customers have requested that interfaces be easier, quicker and less expensive to deploy," stated Dr. Rodger Pinto, CEO of GEMMS. "This has been hard to do given the lack of standards that exist in the industry." He went on to explain, "but now with the new GEMMS LINK technology we are able to quickly and effectively provide high quality interfaces that can be managed by the users with a minimum of IT experience and allows for quick deployment and lower cost to the customer."

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.

Sofie Biosciences, an emerging in vivo imaging diagnostics company focused on PET probes, scanners and chemistry systems,announced today that the National Institute of Health has awarded the company a grant under the Small Business Innovation Research (SBIR) program.

NextGxDx Inc., the most comprehensive online marketplace for genetic testing, yesterday announced that through its work with athenahealth, Inc. (NASDAQ: ATHN), a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination, the companies will deliver an integrated platform to help clinicians more effectively navigate and improve genetic test ordering.NextGxDx is designed to make the complex process of genetic testing simpler. Empowered by an intuitive user interface, physicians and other health care professionals can access up to date listings of all genetic tests from CLIA certified laboratories, order tests online, and receive results electronically. The company's bioinformatics team uses proprietary tools to update and curate test data.

Approximately 50 percent of U.S. hospitals and 40 percent of U.S. physicians in ambulatory practice possess some type of patient portal technology, mostly acquired as a module of their practice management (PM) or electronic health record (EHR) system. While the availability of patient portals does not necessarily translate into active provider or patient use, the technology is emerging as the key platform for various efforts around patient engagement such as access to medical records, communication with providers, education, wellness tracking and e-visits.New analysis from Frost & Sullivan's (http://www.healthcareIT.frost.com) U.S. Patient Portal Market for Hospitals and Physicians: Overview and Outlook, 2012–2017 predicts the market to grow significantly over the next five years. The total U.S. patient portal market for hospitals and physicians earned revenue of $279.8 million in 2012. This is expected to increase steadily, reaching $898.4 million in 2017, representing a 221.1 percent increase. The majority of revenue will primarily result from increased demand driven by myriad forces including the need to meet Stage 2 Meaningful Use (MU) requirements, the growing move to clinical integration and accountable care, and increasing consumer demand for health information technology.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer. This approval is based primarily on data from a Phase II study showing that nearly 40 percent of people receiving the combination of Perjeta, Herceptin (trastuzumab) and docetaxel chemotherapy had no evidence of tumour tissue detectable at the time of surgery (known as a pathological complete response, or pCR). The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the FDA and also the first to be approved based on pCR data.

GE Healthcare announced today that version 11 of its EMR and practice management solution – Centricity Practice Solution – has received Patient-Centered Medical Home (PCMH) pre-validation status from the National Committee for Quality Assurance (NCQA).  With this pre-validation, customers using Centricity Practice Solution 11 can now eliminate some of the documentation required to qualify for PCMH recognition.In response to regulatory change, the healthcare industry is rapidly shifting to new care and payment models. The PCMH model is designed to improve primary care, with a focus on total care coordination through measurement, transparency, and accountability. Practices that have been recognized as Patient Centered Medical Homes by NCQA have often received enhanced reimbursement, increased patient satisfaction, reduced hospitalization rates, and reduced readmission rates.

At the 55th American Society for Radiation Oncology ASTRO annual meeting, Sept. 22-25 in Atlanta, Royal Philips will feature the latest innovations that address efficient and personalized radiation oncology care for patients and their clinicians.

Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that Imaging Specialists of Charleston and Charleston Radiologists, P.A. has selected Merge Healthcare's entire Merge Outpatient Radiology Suite as well as Merge Honeycomb(TM) Archive."Because our organization is committed to providing the highest level of patient care and the latest technology available in our field, we've recently made the decision to align ourselves with a partner who can help to enable our ambitious plans for growth with leading technology," explained Michael Garovich, MD, President of Charleston Radiologists.

Harbin Clinic (Rome, Georgia), the largest privately owned multi-specialty physician group in Georgia, purchased and installed two wireless CARESTREAM DRX-Evolution DR Rooms at its orthopaedic clinic and main clinic. These are the two busiest locations for routine radiology procedures in the group’s 23-site system.“The DRX-Evolution at our orthopaedic clinic has greatly improved our workflow and enhances service for both orthopaedic surgeons and patients,” explains Fred Hastings, Harbin Clinic’s Director of Operations. “We replaced an existing DR system because the DRX-Evolution offered us the benefits of next-generation DR technology—greater flexibility, ease of use, automated hardware features and advanced software functionality.”

Net Health, the leader in software solutions for outpatient specialty care, has announced the availability of The Outpatient Wound Clinic Market Performance Report, developed using data from more than 700,000 patients and more than 1.5 million individual wounds documented in the WoundExpert® software, Net Health's Electronic Medical Record (EMR) for wound management.Based on a review of wound data from 2010 through 2012, the report provides findings about wound clinic performance and clinical outcomes from the provider of the largest EMR solution in the industry.

IBM (NYSE: IBM) today announced that Inland Northwest Health Services is improving patient care via their cloud-based electronic health record services delivered to physicians and medical facilities with IBM server and storage technology.(Logo:  http://photos.prnewswire.com/prnh/20090416/IBMLOGO)The solution based on IBM System x servers, Storwize and DS8000 Storage systems, SAN Volume Controller storage virtualization technology and storage software, ensures high reliability, availability and efficiency for the EHR services INHS provides to 40 hospitals and 750 physicians in the northwest United States.

Cianna Medical, Inc., a women’s health company, today announced results of two new studies showing excellent longer-term outcomes with the SAVI® breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival.

UltraSPECT, a leading provider of image reconstruction technology that reduces radiopharmaceutical dose and acquisition time for nuclear medicine (NM) exams, announces today that study data has shown UltraSPECT solutions are a viable method for meeting American Society of Nuclear Cardiology (ASNC) low dose guidelines. Furthermore, technologists are able to rely on their existing imaging protocols, providing added confidence in overall results. UltraSPECT will be demonstrating this solution to conference attendees at the upcoming ASNC Annual Meeting, September 26-29, in Chicago.“What this preliminary data shows us is that healthcare facilities do not have to change their standard imaging protocols to meet ASNC guidelines to lower dose,” explained Gordon DePuey, MD, director of Nuclear Medicine at St. Luke’s-Roosevelt Hospital, New York. “I am looking forward to seeing the great progress that the cardiovascular imaging community can make in 2014 as proven and viable solutions are applied to lower the dose for the benefit of patients and to continue to advance healthcare.”

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a €206K firm contract with one of its top 10 biopharmaceutical company client. The contract covers the implementation of an exploratory imaging biomarker, tumor volume, in a first-in-man phase I study on adult patients with advanced malignant solid tumors.  Within the framework of the contract, Progression Free Survival (PFS) will be measured on patients enrolled with RECIST 1.1 1. This widely-used standard criterion for response evaluation in solid tumors is based on lesion axial diameter measurements. In parallel, MEDIAN will implement an exploratory imaging biomarker based on tumor volume that provides more accurate and earlier information regarding patient response to therapy.

ITelagen, Inc., a leading provider of healthcare IT support announced the immediate availability of NextGenAnywhere™, a technology that delivers the NextGen® Ambulatory EHR to mobile devices. Now available for iPad and Android tablet mobile devices, NextGenAnywhere is powered by ITelagen's innovative EHRAnywhere™ platform to enable physicians the freedom and flexibility to access patient medical data and applications – where and when they are needed. NextGen Healthcare Information Systems, LLC, is a leading provider of healthcare information systems and connectivity solutions and a wholly owned subsidiary of Quality Systems, Inc. (NASDAQ: QSII).As a NextGen® Certified Partner and VAR (Value Added Reseller), ITelagen is offering the NextGenAnywhere technology to provide physicians and staff with on-demand access to the application, enabling maximum productivity and mobility with their EHR.